The collaboration between Roche and Nurix on bexobrutideg represents a significant advancement in the treatment of B-cell malignancies and expands Roche's therapeutic reach into immunology and neurology. This partnership could position Roche to capture a larger share of the growing BTK inhibitor market, addressing unmet needs and enhancing its competitive edge. Assessment grounded in 9 ranked evidence items (8 high-relevance).